Full Breakdown
Eli Lilly Posts 48% Revenue Jump in Q2 2026 on Diabetes and Obesity Drug Demand
By Drooid · · How we work
Core Event – Q2 2026 Financial Results
Eli Lilly reported a 48% year-over-year revenue increase in Q2 2026, reaching $22.97 billion. Earnings per share rose to $7.94 GAAP and $8.38 non-GAAP, up 26% and 33% respectively. The surge stemmed mainly from higher sales of its diabetes drug Mounjaro and obesity drug Zepbound.
Background & Context – Growing Need for Diabetes and Obesity Therapies
The World Health Organization projects that one in six people worldwide will be at least 60 years old by 2030, boosting demand for chronic-disease treatments. Eli Lilly’s GLP-1-based portfolio is a key part of that market.
Data & Statistics
| Metric | Figure | Source |
|---|---|---|
| Total Q2 2026 revenue | $22.97 billion | Company report |
| Revenue growth YoY | 48% | Company report |
| Sales volume increase | 60% | Company report |
| Average selling price change | -13% | Company report |
| U.S. revenue | $14.4 billion (+33%) | Company report |
| International revenue | $8.6 billion (+80%) | Company report |
| Gross margin | 85.8% ($19.7 billion) | Company report |
| R&D expense | $3.8 billion | Company report |
| Marketing, selling & admin expense | $3.4 billion | Company report |
| Mounjaro sales | $9.94 billion (91% YoY) | Company report |
| Zepbound sales | $4.93 billion (46% YoY) | Company report |
| Combined Mounjaro + Zepbound sales | $14.87 billion (65% of total) | Company report |
| Non-GAAP EPS guidance (2026) | $35.50–$36.50 | Management |
| Full-year 2026 revenue guidance | $85–$87 billion (up from $82 billion) | Management |
| Performance-margin outlook (non-GAAP) | 49%–50.5% (up from 47%–48.5%) | Management |
| New manufacturing investment | $4.5 billion in Indiana; $750 million with Resilience in Cincinnati | Management |
| Retatrutide filing target | Q1 2027 (U.S. FDA) | Management |
| Recent acquisitions | Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, Atai Beckley | Management |
Official Statements & Responses
- Revenue Guidance: Management lifted the 2026 outlook to $85–$87 billion, citing weight-management demand and expanded capacity.
- Pricing Dynamics: A 13% price decline reflects Mounjaro’s inclusion on China’s National Reimbursement Drug List.
- Manufacturing Expansion: An additional $4.5 billion will expand Indiana facilities; a $750 million partnership with Resilience will boost Cincinnati capacity for KwikPen devices.
- Pipeline Progress: Investigational drug retatrutide is slated for a U.S. FDA filing in Q1 2027.
- Acquisition Strategy: Recent deals add platforms such as Orna and Ajax to broaden infectious-disease and metabolic pipelines.
Why It Matters – Market and Investor Implications
The revenue acceleration highlights the commercial strength of GLP-1 therapies in diabetes and obesity. Raising guidance and investing in manufacturing signal confidence in sustaining growth, while price pressure in China shows sensitivity to reimbursement policies. For investors, strong top-line growth, high margins, and a diversified pipeline present a compelling long-term thesis.
What’s Next – Near-Term Outlook
- Regulatory Milestone: Retatrutide filing in Q1 2027 could add a third GLP-1-type obesity product.
- Full-Year Performance: The company aims to meet its $85–$87 billion revenue target, driven by Mounjaro, Zepbound, and the oral weight-loss drug Foundayo.
- Manufacturing Capacity: Ongoing projects in Indiana and Cincinnati should increase throughput and ease supply constraints as GLP-1 demand expands.